NCT00945958 is a Phase 3 clinical trial of SPARC0913 in Open Angle Glaucoma, sponsored by Sun Pharma Advanced Research Company Limited.

Who is sponsoring NCT00945958?

NCT00945958 is sponsored by Sun Pharma Advanced Research Company Limited.

What drugs are being tested in NCT00945958?

Interventions in NCT00945958: SPARC0913.

What condition does NCT00945958 study?

NCT00945958 studies Open Angle Glaucoma, Ocular Hypertension.

Is NCT00945958 still recruiting?

NCT00945958 is currently completed. Last updated 6 March 2021.

Are results published for NCT00945958?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-03-06 · How we verify

NCT00945958

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension

Completed Phase 3 Results posted Last updated 6 March 2021

What this trial tests

Phase 3 trial testing SPARC0913 in Open Angle Glaucoma in 161 participants. Completed in 1 June 2012.

Timeline

1 November 2010

Primary endpoint
1 June 2012

1 June 2012

Quick facts

Lead sponsor	Sun Pharma Advanced Research Company Limited
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	161
Start date	1 November 2010
Primary completion	1 June 2012
Estimated completion	1 June 2012
Sites	1 location across United States

Drugs / interventions tested

SPARC0913 — full drug profile →

Conditions studied

Open Angle Glaucoma — all drugs for Open Angle Glaucoma →
Ocular Hypertension — all drugs for Ocular Hypertension →

Sponsor

Sun Pharma Advanced Research Company Limited — full company profile →

Who can join

18 and older, any sex, with Open Angle Glaucoma or Ocular Hypertension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Subjects With AEs
Time frame: 24 weeks
Subjects with treatment emergent adverse events

Sponsor's own description

The purpose of this study is to evaluate the long-term safety of SPARC0913. A multicenter, open label, non-randomized, uncontrolled, single group assignment, safety study of subjects with primary open angle glaucoma or ocular hypertension is planned. Subjects will receive study medication for a period of 24-weeks.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Open-Label Extension Study Comparing Latanoprost 0.005% Without vs With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension.
Shen Lee B, Malhotra R, Sall K, Mitchell B, et al · · 2022 · cited 3× · PMID 35898518 · DOI 10.2147/opth.s367756

Verify or expand the search:

Other recruiting trials for Open Angle Glaucoma

Currently open trials in the same condition.

NCT07228221 — Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma · Phase 4 · recruiting
NCT06883123 — Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost · Phase 4 · recruiting
NCT06666855 — A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China · Phase 3 · active not recruiting
NCT06246136 — Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery · NA · recruiting
NCT06061718 — Travoprost Intraocular Implant in Conjunction With Cataract Surgery · Phase 3 · active not recruiting

Other Sun Pharma Advanced Research Company Limited trials

Trials by the same sponsor.

NCT04942054 — A Study in Patients With Advanced Breast Cancer · Phase 1 · terminated
NCT04332549 — To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Rec · Phase 1 · withdrawn
NCT04242953 — Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subj · Phase 1 · completed
NCT03655236 — PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase · Phase 2 · terminated
NCT02597465 — A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 · Phase 3 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00945958 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Pharma Advanced Research Company Limited
Last refreshed: 6 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00945958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing